Andrew Pollard speaking at Covid-19 press briefing

The transcript discusses the promising results of a vaccine study, highlighting a 90% efficacy rate in one arm of the study. The focus is on providing data to regulators for potential licensure and the importance of global distribution, especially in partnership with AstraZeneca. The vaccine can be stored at fridge temperatures, facilitating worldwide access. The ethical stance of a not-for-profit approach during the pandemic is emphasized. The transcript concludes with optimism for the future and the importance of protecting each other with new treatments.

What are the expectations for the vaccine's approval process?

What is the vision for equitable access to the vaccine?